Table 2.

Drugs under development for tinnitus

Compund	Company	Indication	Stage of development	Mechanism of action
Neramexane	Merz	Tinnitus, Alzheimer’s disease, nystagmus, pain	Phase III	NMDA receptor antagonist, blocker of alpha9 and alpha10 nicotinic cholinergic receptors
LidoPAIN TV	Epicept	Tinnitus, vertigo	Phase II	Local anesthetic of periauricular nerve endings
SPI-1005 / ebselen	Sound pharmaceuticals	Prevention and treatment of noise induced hearing loss and tinnitus	PhaseII	antioxidant
AM-101	Auris Medical	Tinnitus and hearing loss	Phase II	NMDA antagonist
AM-102	Auris Medical	Prevention and treatment of tinnitus	preclinical	Unidentified pharmacological activity
Vestipitant + paroxetine	Glaxo-Smith-Kline	Depression, anxiety, tinnitus	Phase II	neurokinin-1 (N K-1) receptor antagonist + serotonine reuptake inhibitor
EGb-761	Ipsen	Cognitive disorder, Alzheimer’s disease, vertigo, tinnitus	Phase I	Free radical scavanger